Bergenbio ASA (OL:BGBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Bergenbio ASA (BGBIO)
Bergenbio ASA (OL:BGBIO) has a market capitalization of $7.75 Million (Nkr73.62 Million) as of June 17, 2026. Listed on the OL stock exchange, this Norway-based company holds position #27652 globally and #252 in its home market, demonstrating a -61.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bergenbio ASA's stock price Nkr0.47 by its total outstanding shares 156641128 (156.64 Million). Review BGBIO current and long-term liabilities to assess the company's total debt and financial obligations.
Bergenbio ASA Market Cap History: 2017 to 2025
Bergenbio ASA's market capitalization history from 2017 to 2025. Data shows change from $28.97 Billion to $7.75 Million (-61.96% CAGR).
Bergenbio ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bergenbio ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
159.02x
Bergenbio ASA's market cap is 159.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $37.37 Billion | $2.33 Million | -$191.75 Million | 16002.52x | N/A |
| 2019 | $34.08 Billion | $8.90 Million | -$199.28 Million | 3828.89x | N/A |
| 2020 | $45.82 Billion | $601.00K | -$257.03 Million | 76246.49x | N/A |
| 2021 | $28.86 Billion | $774.00K | -$309.36 Million | 37287.69x | N/A |
| 2022 | $10.63 Billion | $389.00K | -$302.12 Million | 27328.10x | N/A |
| 2023 | $458.23 Million | $354.00K | -$190.40 Million | 1294.44x | N/A |
| 2024 | $134.85 Million | $848.00K | -$139.28 Million | 159.02x | N/A |
Competitor Companies of BGBIO by Market Capitalization
Companies near Bergenbio ASA in the global market cap rankings as of June 17, 2026.
Key companies related to Bergenbio ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Bergenbio ASA Historical Marketcap From 2017 to 2025
Between 2017 and today, Bergenbio ASA's market cap moved from $28.97 Billion to $ 7.75 Million, with a yearly change of -61.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Nkr7.75 Million | -94.25% |
| 2024 | Nkr134.85 Million | -70.57% |
| 2023 | Nkr458.23 Million | -95.69% |
| 2022 | Nkr10.63 Billion | -63.17% |
| 2021 | Nkr28.86 Billion | -37.02% |
| 2020 | Nkr45.82 Billion | +34.47% |
| 2019 | Nkr34.08 Billion | -8.80% |
| 2018 | Nkr37.37 Billion | +28.99% |
| 2017 | Nkr28.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Bergenbio ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.75 Million USD |
| MoneyControl | $7.75 Million USD |
| MarketWatch | $7.75 Million USD |
| marketcap.company | $7.75 Million USD |
| Reuters | $7.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.